Navigation Links
Resverlogix Eliminates Sixty Percent of Remaining Debt

Restructure allows new scientific and business development flexibility

TSX Exchange Symbol: RVX

CALGARY, Oct. 15 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has redeemed USD$10 million or approximately 60% of its remaining USD$17.3 million debenture.

Donald McCaffrey, President and CEO of Resverlogix stated, "The economic environment remains very volatile and challenging for companies around the globe. This action limits our dilution on set terms that protect shareholders value and it enhances our flexibility to proceed with our ongoing scientific and business development plans. The US $10 million redemption will consist of 2.4 million common shares with a value of US $5.5 million and US $4.5 million cash. Under the terms of the amendment, the conversion price has been amended to a five day volume weighted average price of $3.07 less 15% in exchange for debenture holders agreeing to restrict any put options until March 31, 2009. Along with the removal of future certain dilution factors the Company has also gained the option to buy out any remaining debenture at a 25% premium."

The following are key terms of the restructured convertible debenture:

- In addition to the March 31, 2009 restriction on the put option, the

ability to put to the Company in common shares has been waived by the

debt holders.

- The remaining principal balance of $278,000 carrying a 15% interest

rate from the January 2007 convertible debenture has been reduced to

12% and rolled into the remaining convertible debt instrument.

- Mandatory conversion of the entire debt at the Company's option at

$5.22, subject to certain trading conditions being met.

- The 1,467,349 outstanding warrants have been repriced to $3.07.

To assist shareholders with understanding the salient and beneficial points to this amendment Resverlogix will post key facts to SEDAR.

Rodman & Renshaw, LLC served as an advisor to the company.

The transactions are subject to TSX approval.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Issues a Management Statement
2. Resverlogix Board of Directors Update
3. Resverlogix Notice of Conference Call & Webcast
4. Jan Gray Joins Resverlogix Board of Directors
5. Resverlogixs Lead Drug Featured in Key Scientific Publication
6. Industry Leaders Select Resverlogixs RVX-208
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Resverlogix Notice of Conference Call & Webcast
9. Resverlogix Share Option Extension
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
Post Your Comments:
(Date:11/24/2015)... - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" ... , President and Chief Executive Officer of ProMetic, will be ... th Annual Healthcare Conference to be held at the ... st , at 8.50am (ET) and ProMetic,s management team ... presentation will be available live via a webcast accessible at ...
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
(Date:11/24/2015)... Nov. 24, 2015 According to two new studies, ... This is something that many doctors, scientists, and public health ... remains: with fewer PSA tests being done, will there be ... Dr. David Samadi, "Despite the efforts made in ... the second leading cancer cause of death in men, killing ...
(Date:11/23/2015)... 2015 China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... preliminary unaudited financial results for the second quarter and ... 2015. --> --> ... for the second quarter of fiscal 2016 increased by ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
Breaking Biology News(10 mins):